Back to top
more

Labcorp (LH)

(Real Time Quote from BATS)

$235.60 USD

235.60
54,256

+1.22 (0.52%)

Updated Nov 7, 2024 11:13 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

LabCorp (LH) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Beats Q3 Earnings Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 2.67% and 2.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.

Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

LabCorp's (LH) growth in early development and clinical development are expected to have been offset by central labs on the account of a significant slowdown in COVID-related work.

Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing

by Zacks Equity Research

Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.

    BD's (BDX) Latest Collaboration to Boost Patient Outcome

    by Zacks Equity Research

    BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.

    BD (BDX) Ties Up With LabCorp to Boost Patient Outcome

    by Zacks Equity Research

    BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.

    LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View

    by Zacks Equity Research

    LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.

    LabCorp (LH) Q2 Earnings Beat Estimates

    by Zacks Equity Research

    LabCorp (LH) delivered earnings and revenue surprises of 6.21% and 3.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Medical Device Stocks to Watch for Earnings on Jul 28

    by Zacks Equity Research

    Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, TMO and BIO will likely fare this time.

    Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

    by Zacks Equity Research

    AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

    Can LabCorp (LH) Keep the Earnings Surprise Streak Alive?

    by Zacks Equity Research

    LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    LabCorp (LH) to Offer New Test Report for Venom Allergy Testing

    by Zacks Equity Research

    LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.

    LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.

    LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis

    by Zacks Equity Research

    LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.

    LabCorp's (LH) Base Testing Volume Grows, Costs Rise

    by Zacks Equity Research

    LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.

    LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity

    by Zacks Equity Research

    Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.

    LabCorp (LH) to Strengthen Laboratory Footprint in Japan

    by Zacks Equity Research

    LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.

    LabCorp (LH) Partners HealthVerity to Grow in Drug Development

    by Zacks Equity Research

    According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.

    Here's Why Investors Should Retain LabCorp (LH) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.

    LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test

    by Zacks Equity Research

    LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.

    Strength Seen in LabCorp (LH): Can Its 3.7% Jump Turn into More Strength?

    by Zacks Equity Research

    LabCorp (LH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    LabCorp (LH) Rides on Innovations Amid Cost Constraints

    by Zacks Equity Research

    LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.